How much funding has Grannus Therapeutics raised?

Grannus Therapeutics has raised $2.9M in total funding, most recently a Seed round.

Who are Grannus Therapeutics's investors?

Grannus Therapeutics's investors include Pit Road Fund, Angel investors, Plug and Play, Elevate Capital.

When was Grannus Therapeutics founded?

Grannus Therapeutics was founded in 2019.

Where is Grannus Therapeutics headquartered?

Grannus Therapeutics is headquartered in Indianapolis, Indiana, United States.

What industry is Grannus Therapeutics in?

Grannus Therapeutics operates in Healthcare.

Grannus Therapeutics

Redefining What's Possible in Targeted Cancer Therapy

Indianapolis, United States · Founded 2019 · $2.9M raised

Healthcare

Headquarters: Indianapolis, Indiana
Founded: 2019
Business Model: B2B
Website: grannustherapeutics.com

Total Funding: $2.9M
Last Round: $1.1M SeedFeb 2025
Rounds: 3

About

Grannus Therapeutics is a pre-clinical stage biotechnology company developing first-in-class Hsp90β-selective inhibitors for the treatment of multiple solid tumors. Unlike prior pan-Hsp90 inhibitors that failed in clinical trials due to dose-limiting toxicities, Grannus's isoform-selective approach targets the beta version of the Hsp90 protein, delivering potent single-agent efficacy and enabling powerful combinations with approved therapies such as PARP inhibitors. The company's science is rooted in research from the University of Notre Dame and Purdue University, and it operates within the IDEA Center Innovation Park.

Summary

Grannus Therapeutics is a Healthcare company based in Indianapolis, United States, founded in 2019. It has raised $2.9M in total across 3 rounds, most recently a $1.1M Seed round in Feb 2025. Investors include Pit Road Fund, Angel investors and Plug and Play.